Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-typeable Haemophilus influenzae (NTHi) bacterial antigens are a collection of surface-exposed proteins and structures on NTHi strains, which are characterized by the absence of a polysaccharide capsule (Murphy et al., 2009, Journal of Clinical Investigation). These antigens, such as Protein D, Protein E, Protein F, and PilA, are essential for the bacterium's ability to adhere to and colonize the human respiratory epithelium (Pichichero, 2013, Expert Review of Vaccines). NTHi is a leading cause of acute otitis media in children and a major contributor to the pathogenesis and exacerbation of Chronic Obstructive Pulmonary Disease (COPD) in adults (Wilkinson et al., 2017, European Respiratory Journal). Therapeutic development focuses on these antigens as vaccine candidates to induce protective immunity, specifically through the production of opsonizing antibodies that facilitate bacterial clearance (Langereis & de Jonge, 2015, Frontiers in Cellular and Infection Microbiology). Current clinical efforts, such as the development of multicomponent vaccines, aim to provide broad protection against diverse NTHi strains by targeting conserved surface proteins (GSK, 2024, Pipeline). These antigens are also being explored as targets for monoclonal antibodies to prevent colonization in high-risk populations (Su et al., 2020, Vaccines).
Vaccine-mediated induction of opsonophagocytic antibodies and inhibition of bacterial adherence to host tissues.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-typeable Haemophilus influenzae bacterial antigens (NTHi antigens).